Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
The DOI matches its Crossref record; 158 of the 169 references it cites were found in a registry or an index.
Abstract
Objective: To update the "Testosterone Therapy in Men With Androgen Deficiency Syndromes" guideline published in 2010. Participants: The participants include an Endocrine Society-appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline. Conclusions: We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRT is also contra-indicated in people with (high risk of) prostate cancer, a history of breast cancer, thrombophilia, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, and myocardial infarction or stroke within the last 6 months [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It suppresses spermatogenesis, and thus, cannot be used in patients with a desire to have children in the near future.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It may result in gynecomastia, acne, testicular atrophy and erythrocytosis.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“The Endocrine Society guideline emphasizes the importance of lifestyle changes in men with central hypogonadism and comorbidities [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“Hyperprolactinemia also suppresses the secretion of GnRH and the response of gonadotropins to GnRH secretion.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationHeidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“culated from TT, SHBG, and albumin levels (23, 24).”
Harrison's Principles of Internal Medicine
Massarelli, J. J. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340300091039 · Cited by 1,132
Research works printed but not linked: 1
- Bhasin, 2015, Disorders of the testes and male reproductive system
Cited by
Items 501–600 of 1,733
Chasland, L. C., Knuiman, M. W., Divitini, M., Murray, K., Handelsman, D. J., Flicker, L. A., Hankey, G. J., Almeida, O. P., Golledge, J., Ridgers, N. D., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13905 · Cited by 15
CF and male health: Sexual and reproductive health, hypogonadism, and fertility
Khan, F. N., Mason, K. A., Roe, A. H., & Tangpricha, V. (2021) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2021.100288 · Cited by 16
Honig, S. C., Gittelman, M., Kaminetsky, J. C., Wang, C., Amory, J. K., Rohowsky, N., Dudley, R. E., Seo, B. W., Newmark, J., & Swerdloff, R. S. (2022) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2022.09.002 · Cited by 15
Self-citationHostnik, B., Tonin, G., Janež, A., & Klen, J. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70099 · Cited by 30
“It can lead to decreased physical energy, reduced motivation, irritability, sleep disturbances and depressed mood in men [114].”
Symptoms of Late-Onset Hypogonadism in Men
Snyder, P. J. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.04.001 · Cited by 16
Self-citationZitzmann, M., Rastrelli, G., Murray, R. D., Edwards, D. A., Reisman, Y., Rao, P. M., Sahi, A., Jones, T. H., Ferlin, A., Armeni, E., et al. (2025) · Andrology · doi:10.1111/andr.70062 · Cited by 21
Swislocki, A., & Eisenberg, M. L. (2024) · The World Journal of Men s Health · doi:10.5534/wjmh.240029 · Cited by 18
“…testosterone deficiency (in whom the diagnosis has been confirmed by repeated measurements of total, and in some cases, free, testosterone as well as clinical symptoms) to induce and maintain secondary sex characteristics after a discussion of potential benefits and risks of therapy [12-14].”
Novel androgen therapies including selective androgen receptor modulators
Kang, J., Chen, R., Tharakan, T., & Minhas, S. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101686 · Cited by 16
Testosterone replacement therapy and the risk of adverse cardiovascular outcomes and mortality
Pantalone, K. M., George, J., Ji, X., Kattan, M. W., Milinovich, A., Bauman, J. M., Burguera, B. G., Zimmerman, R. S., & Misra‐Hebert, A. D. (2019) · Basic and Clinical Andrology · doi:10.1186/s12610-019-0085-7 · Cited by 14
Falqueto, H., dos Santos, M. R., & Manfredi, L. H. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.838526 · Cited by 18
Prostate Risk and Monitoring During Testosterone Replacement Therapy
Bhasin, S., & Thompson, I. M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae334 · Cited by 18
Self-citationOptimizing Diagnostic Accuracy and Treatment Decisions in Men With Testosterone Deficiency
Bhasin, S., & Ozimek, N. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.08.002 · Cited by 15
Self-citationIs There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?
Giagulli, V. A., Silvestrini, A., Bruno, C., Triggiani, V., Mordente, A., & Mancini, A. (2020) · International Journal of Endocrinology · doi:10.1155/2020/9649838 · Cited by 14
“, obesity, metabolic syndrome, diabetes mellitus, and so on) have been suggested [3, 4].”
BackgroundFelicetti, F. C., Castiglione, A., Biasin, E., Fortunati, N., Dionisi‐Vici, M., Matarazzo, P., Ciccone, G., Fagioli, F., & Brignardello, E. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28709 · Cited by 15
Kallman syndrome and central non-obstructive azoospermia
Thakker, S. S., Persily, J. B., & Najari, B. B. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101475 · Cited by 15
Aleksova, J., Rodríguez, A. J., McLachlan, R. I., Kerr, P. G., Milat, F., & Ebeling, P. R. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0483-3 · Cited by 14
Endocrine health in survivors of adult-onset cancer
Link, C. S., Göbel, A., Jaschke, N., & Rachner, T. D. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00088-3 · Cited by 19
Matsumoto, A. M. (2019) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2019.04.004 · Cited by 17
Self-citationManagement of vasomotor symptoms in cancer patients
Zhu, L., Hshieh, T. T., Iyer, T. K., Morgans, A. K., & Hamnvik, O. R. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf002 · Cited by 23
Testosterone therapy and secondary erythrocytosis
White, J. T., Petrella, F., & Ory, J. (2022) · International Journal of Impotence Research · doi:10.1038/s41443-021-00509-5 · Cited by 16
“More practical definitions vary depending on the guideline, ranging from a hematocrit of 48% up to 55% [1, 14, 15].”
BackgroundInfluentialDe Vincentis, S., Decaroli, M. C., Milic, J., Fanelli, F., Tartaro, G., Diazzi, C., Mezzullo, M., De Santis, M. C., Roli, L., Trenti, T., et al. (2023) · Andrology · doi:10.1111/andr.13372 · Cited by 14
Androgen Society Position Paper on Cardiovascular Risk With Testosterone Therapy
Morgentaler, A., Dhindsa, S., Dobs, A. S., Hackett, G. I., Jones, T. H., Kloner, R. A., Miner, M. M., Zitzmann, M., & Traish, A. M. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.08.008 · Cited by 21
Langlois, F., Suarez, G. M., & Fleseriu, M. (2020) · F1000Research · doi:10.12688/f1000research.22683.1 · Cited by 15
Testosterone and cardiovascular health
Elagizi, A., Gersh, F. L., Lavie, C. J., Laukkanen, J. A., & O’Keefe, J. H. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad513 · Cited by 17
Vincentis, S. D., Greco, C., Fanelli, F., Decaroli, M. C., Diazzi, C., Mezzullo, M., Milić, J., Santis, M. C. D., Roli, L., Pagotto, U., et al. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02375-6 · Cited by 14
“…gonadal function in MLWH in which measurement of total T, E2, DHT, and E1were obtained by the recommended analytical technology (LC–MS/MS) alongside SHBG in order to calculate free T that is recognized to be the most reliable biomarker to detect the gonadal status in these patients [58, 76, 77].”
BackgroundMethodDiagnosis of hypogonadism in ageing men
Kaufman, J. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09763-4 · Cited by 20
Benefits and Risks of Testosterone Treatment of Older Men with Hypogonadism
Galbiati, F., Goldman, A. L., Gattu, A. K., Guzelce, E. C., & Bhasin, S. (2022) · Urologic Clinics of North America · doi:10.1016/j.ucl.2022.07.011 · Cited by 16
Self-citationFantus, R. J., Na, R., Wei, J., Shi, Z., Resurreccion, W. K., Halpern, J. A., Franco, O. E., Hayward, S. W., Isaacs, W. B., Zheng, S. L., et al. (2021) · European Urology Open Science · doi:10.1016/j.euros.2021.04.010 · Cited by 15
“Manifestations of LowT are variable, and most guidelines do not suggest replacement unless men have symptoms consistent with testosterone deficiency (TD) [7 – 9].”
Corona, G., Rastrelli, G., Sparano, C., Vignozzi, L., Sforza, A., & Maggi, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2422547 · Cited by 18
Pellikaan, K., Nguyen, N., Rosenberg, A. G. W., Coupaye, M., Goldstone, A. P., Höybye, C., Markovic, T., Grugni, G., Crinò, A., Caixàs, A., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad312 · Cited by 14
Taniguchi, H., Shimada, S., & Kinoshita, H. (2021) · Urologia Internationalis · doi:10.1159/000520135 · Cited by 15
Testosterone and Obesity in an Aging Society
Tsutsumi, T., & Tsuchiya, K. (2025) · Biomolecules · doi:10.3390/biom15111521 · Cited by 21
“However, they require patients to master self-injection techniques, which may reduce adherence [157,179].”
InfluentialLi, L., Ju, H., Jin, H., Chen, H., Sun, M., & Zhou, Z. (2022) · Journal of Healthcare Engineering · doi:10.1155/2022/3630429 · Cited by 17
Jayasena, C. N., de Silva, N. L., O’Reilly, M., MacKenzie, F., Marrington, R., Jones, H. T., Livingston, M. A., Downie, P., Hackett, G. I., Ramachandran, S., et al. (2023) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632231179022 · Cited by 15
“Guidelines agree that total testosterone >12 nmol/L is unlikely to represent hypogonadism.(1,19) One exception would be when the luteinising hormone (LH) level is raised and there is a concern about subclinical/compensated primary hypogonadism, or androgen receptor cytosine-adenine-guanine (CAG) repeat polymorphism.”
BackgroundSelf-citationGosmanov, A. R., Gemoets, D. E., & Schumacher, K. A. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02350-1 · Cited by 17
“It is well established from the pre-SGLT-2i prescription era studies that chronic therapy of hypogonadal men with testosterone will increase hematocrit during the treatment course, also increasing relative risk of de novo erythrocy-tosis by eightfold [10].”
InfluentialThe role of clomiphene citrate in late onset male hypogonadism
Ros, C. T. D., Ros, L. U. D., & da Ros, J. P. U. (2022) · International braz j urol · doi:10.1590/s1677-5538.ibju.2021.0724 · Cited by 16
“This decrease is due to a smaller number and minor function of Leydig cells, changes in the hypothalamus-pituitary-gonadal axis and increased sex hormone binding globulin (SHBG) (3, 4, 10).”
BackgroundInfluentialUse of calculated free testosterone in men: advantages and limitations
Nyamaah, J. A., Narinx, N., Antonio, L., & Vanderschueren, D. (2024) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000891 · Cited by 15
“Due to the complexity of measuring free T, clinicians typically rely on calculators to estimate its concentrations.”
Tienforti, D., Castellini, C., Giulio, F. D., Totaro, M., Dalmazio, G., Spagnolo, L., Muselli, M., Corona, G., Baroni, M. G., & Barbonetti, A. (2023) · Andrology · doi:10.1111/andr.13373 · Cited by 17
Lazzerini, P. E., Cantara, S., Bertolozzi, I., Accioli, R., Salvini, V., Cartocci, A., D’Errico, A., Sestini, F., Bisogno, S., Cevenini, G., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.023371 · Cited by 13
Androgenic Steroids Use and Abuse
Thirumalai, A., & Anawalt, B. D. (2022) · Urologic Clinics of North America · doi:10.1016/j.ucl.2022.07.008 · Cited by 21
The medicalization of testosterone: reinventing the elixir of life
Gagliano‐Jucá, T., Álvarez, M., & Basaria, S. S. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09751-8 · Cited by 16
“Indeed, the Endocrine Society’s clinical practice guidelines on male hypogonadism recommend treatment with 5–10 mg of testosterone daily [5].”
BackgroundIndirli, R., Cangiano, B., Profka, E., Mantovani, G., Persani, L., Arosio, M., Bonomi, M., & Ferrante, E. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00781 · Cited by 14
The Role of Aromatase Inhibitors in Male Prolactinoma
Akirov, A., & Rudman, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041437 · Cited by 16
“This decrease in dopamine agonist sensitivity following the introduction of testosterone therapy is likely secondary to the aromatization of testosterone to estrogen, which can stimulate the proliferation and hyperplasia of lactotroph cells in the pituitary, inducing resistance to dopamine agonists [24].”
BackgroundObstructive Sleep Apnea Is Associated With Low Testosterone Levels in Severely Obese Men
Tančić‐Gajić, M., Vukčević, M., Ivović, M., Marina, L., Arizanović, Z., Soldatović, I., Stojanovic, M. M., Đogo, A., Kendereški, A., & Vujović, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.622496 · Cited by 16
Bolat, M. S., Özbek, L. M., Şahin, B., Yılmaz, M., Kocamanoğlu, F., Büyükalpelli, R., Sünter, A. T., & Aşçı, R. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14111 · Cited by 13
Gurayah, A. A., Mason, M. M., Masterson, J. M., Kargi, A. Y., & Ramasamy, R. (2022) · International Journal of Impotence Research · doi:10.1038/s41443-022-00533-z · Cited by 16
“Obesity has also been associated with male hypogonadism, a clinical syndrome resulting from failure of the testis to produce physiological concentrations of testosterone (T), sperm, or both [4].”
BackgroundAndrogen Excess and Deficiency: Analytical and Diagnostic Approaches
Heijboer, A. C., & Hannema, S. E. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad146 · Cited by 14
Aging and sex hormones in males
Decaroli, M. C., Vincentis, S. D., & Rochira, V. (2021) · Vitamins and hormones · doi:10.1016/bs.vh.2020.12.014 · Cited by 18
Extremely low testosterone due to relative energy deficiency in sport: a case report
Narla, A., Kaiser, K., & Tannock, L. R. (2019) · AACE Clinical Case Reports · doi:10.4158/accr-2018-0345 · Cited by 6
“Male hypogonadism may be caused by congenital, structural, or destructive disorders, resulting in permanent hypothalamic, pituitary, or testicular dysfunction, or it can be functional, usually reversible, caused by conditions that suppress gonadotropin and testosterone concentrations (5).”
BackgroundKeihani, S., Wright, L. N., Alder, N. J., Jiang, J., Cheng, P. J., Stoddard, G. J., Pastuszak, A. W., Deibert, C. M., & Hotaling, J. M. (2020) · Urology · doi:10.1016/j.urology.2020.04.074 · Cited by 13
Therapeutic effects of androgens for cachexia
Giovanelli, L., & Quinton, R. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101598 · Cited by 15
Koh, K., Kim, S. S., Kim, J.-S., Jung, J. G., Yoon, S. J., Suh, W. Y., Kim, H. G., & Kim, N. (2022) · Korean Journal of Family Medicine · doi:10.4082/kjfm.21.0173 · Cited by 15
Khera, M., Torres, L. O., Grober, E. D., Morgentaler, A., Miner, M. M., Jones, T. H., Mills, J. N., & Salonia, A. (2025) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeaf036 · Cited by 26
Prognostic value of total testosterone levels in patients with acute coronary syndromes
Gencer, B., Vuilleumier, N., Nanchen, D., Collet, T., Klingenberg, R., Räber, L., Auer, R., Carballo, D., Carballo, S., Aghlmandi, S., et al. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319853343 · Cited by 13
Sood, A., Hosseinpour, A., Sood, A., Avula, S., Durrani, J., Bhatia, V., & Gupta, R. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.09.012 · Cited by 22
A Systematic Review of Testosterone Therapy in Men With Spinal Cord Injury or Traumatic Brain Injury
McLoughlin, R. J., Lu, Z., Warneryd, A. C., & Swanson, R. L. (2023) · Cureus · doi:10.7759/cureus.34264 · Cited by 16
“Worth mentioning, the Endocrine Society guidelines do not recommend testosterone therapy in men with prostate cancer, breast cancer, PSA greater than 4 ng/ml or greater than 3 ng/ml in individuals at high risk for prostate cancer, hematocrit greater than 54%, uncontrolled congestive heart failure, history of myocardia…”
BackgroundDifferences in Penile Hemodynamic Profiles in Patients with Erectile Dysfunction and Anxiety
Cannarella, R., Calogero, A. E., Aversa, A., Condorelli, R. A., & Vignera, S. L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030402 · Cited by 14
“The exclusion criteria were given by the presence of hypogonadism (total testosterone <264 ng/dL confirmed by at least two measurements [14]), hyperprolactinemia, hypothyroidism, diabetes mellitus, hypertension, dyslipidemia, overweight, and obesity; anamnestic factors or lifestyles potentially able to cause organic E…”
BackgroundA comprehensive review on transdermal patches as an efficient approach for the delivery of drug
Ashfaq, A., Riaz, T., Waqar, M. A., Zaman, M., & Majeed, I. (2024) · Polymer-Plastics Technology and Materials · doi:10.1080/25740881.2024.2317408 · Cited by 21
Graziani, A., Grande, G., & Ferlin, A. (2023) · Frontiers in Reproductive Health · doi:10.3389/frph.2023.1219239 · Cited by 17
Reducing the off-target endocrinologic adverse effects of azole antifungals—can it be done?
Balcerek, M. I., Stewart, A. G., Chapman, P. R., & Lazarus, S. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106587 · Cited by 16
Male Gonadal Function After Pediatric Hematopoietic Stem Cell Transplantation: A Systematic Review
Mathiesen, S., Andrés‐Jensen, L., Nielsen, M. M., Sørensen, K., Ifversen, M., Jahnukainen, K., Juul, A., & Müller, K. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.05.036 · Cited by 13
Figueiredo, M. G., Gagliano‐Jucá, T., & Basaria, S. S. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.12.002 · Cited by 13
Lachâtre, M., Pasquet, A., Ajana, F., Soudan, B., Quertainmont, Y., Lion, G., Durand, E., Bocket, L., Mole, M., Cornavin, P., et al. (2022) · AIDS · doi:10.1097/qad.0000000000003176 · Cited by 17
“Current Endocrine Society clinical guidelines recommend adjuvant treatment with testosterone at least in the short term, in HIVinfected men with weight loss and low testosterone levels, to promote gains in muscle strength and lean body mass [12,13].”
BackgroundMethodInfluentialLiu, B., Zheng, S., Tang, H., Liu, Q., Li, H., Gao, B., Zhao, X., & Sun, F. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112460 · Cited by 11
Late‐onset hypogonadism a challenging task for the andrology field
Corona, G., & Krausz, C. G. (2020) · Andrology · doi:10.1111/andr.12917 · Cited by 14
Depressive symptoms are not associated with long-term integrated testosterone concentrations in hair
Walther, A., Wehrli, S., Kische, H., Penz, M. S., Wekenborg, M., Gao, W., Rothe, N., Beesdo‐Baum, K., & Kirschbaum, C. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1795253 · Cited by 10
“…neither treatment guidelines for depression (National Collaborating Centre for Mental Health UK 2010), nor clinical practice guidelines for testosterone treatment in men (Bhasin et al. 2018) or women (Wierman et al. 2014) support testosterone administration for countering depressive disorders.”
BackgroundCardiometabolic Disorder and Erectile Dysfunction
Adeyemi, D. H., Arokoyo, D. S., Hamed, M. A., Dare, A., Oyedokun, P. A., & Akhigbe, R. E. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01361-2 · Cited by 20
“Contrary to the report that a minimum serum level of testosterone of about 8 nmol/l is required for normal erectile function, some hypogonadal men have been reported to exhibit an almost normal sexual performance despite testosterone levels below this value [35].”
Kaltsas, A., Dimitriadis, F., Zachariou, A., Koukos, S., Chrisofos, M., & Sofikitis, N. (2026) · Cells · doi:10.3390/cells15020158 · Cited by 12
“For men who are not pursuing fertility, often after completion of https://doi.org/10.3390/cells15020158 family building and commonly beyond reproductive age, TRT can be appropriate for symptom treatment after individualized risk benefit discussion and structured monitoring [75].”
InfluentialMari, Z. M., Smaism, M. F., & Al-Hilli, N. M. (2023) · Medical Journal of Babylon · doi:10.4103/mjbl.mjbl_187_23 · Cited by 15
González-Gil, A. M., Barnouin, Y., Celli, A., Viola, V., Villarreal, M. D., Nava, M. L. D., Sciuk, A., Qualls, C., Armamento‐Villareal, R., & Villareal, D. T. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae249 · Cited by 15
Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
Elston, M. S., Love, A., Kevat, D., Carroll, R. W., Siow, Z. R., Pattison, S. T., Boyle, V., Segelov, E., Strickland, A. H., Wyld, D., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4345 · Cited by 15
An autofluorescence-based isolation of Leydig cells for testosterone deficiency treatment
Luo, P., Feng, X. G., Deng, R., Wang, F., Zhang, Y., Li, X., Zhang, M., Wan, Z., Xiang, A. P., Xia, K., et al. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111389 · Cited by 12
Yeap, B. B., Marriott, R. J., Adams, R., Antonio, L., Ballantyne, C. M., Bhasin, S., Cawthon, P. M., Couper, D. J., Dobs, A. S., Flicker, L. A., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-034777 · Cited by 15
Self-citationUpdate on Physical, Psychological, and Quality of Life Management in Klinefelter Syndrome
Mehmet, B., Dwyer, A. A., Jayasena, C. N., Gillard, S., & Llahana, S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf261 · Cited by 18
Das, G. C., Surya, A., Okosieme, O. E., Vali, A., Tennant, B. P., Geen, J., & Abusahmin, H. (2019) · Endocrine Practice · doi:10.4158/ep-2018-0609 · Cited by 12
Monitoring testosterone replacement therapy with transdermal gel: when and how?
Sansone, A., Sansone, M., Selleri, R., Schiavo, A., Gianfrilli, D., Pozza, C., Zitzmann, M., Lenzi, A., & Romanelli, F. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01082-x · Cited by 9
Sun, K., Wang, C., Lao, G., Lin, D., Huang, C., Li, N., Li, L., Li, F., Xiao, H., & Yan, L. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-033991 · Cited by 12
Testosterone as a Biomarker of Adverse Clinical Outcomes in SARS-CoV-2 Pneumonia
Marinelli, L., Beccuti, G., Zavattaro, M., Cagnina, S., Gesmundo, I., Bona, C., Lopez, C., Scabini, S., Canta, F., Pinna, S. M., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10040820 · Cited by 12
“After a median hospital stay of 10 days, TT and cFT levels improved and reached the low-normal value range, according to current Endocrine Society guidelines [32].”
BackgroundResultInfluentialNovaes, M. T., de Carvalho, O. L. F., Ferreira, P. H. G., Tiraboschi, T. L. N., Silva, C. S., Contreras, J. C. Z., Gomes, C. M., Miranda, E., Júnior, O. A. D. C., & de Bessa, J. (2021) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2021.100538 · Cited by 17
Nordio, M., Kumanov, P., Chiefari, A., & Puliani, G. (2021) · Basic and Clinical Andrology · doi:10.1186/s12610-021-00146-4 · Cited by 14
“Nowadays, the testosterone replacement therapy (TRT) is universally accepted as the main treatment for pathological hypogonadism in men, but its role in functional hypogonadism is unclear [1, 7, 13, 14].”
BackgroundSemen analysis: a workflow for an appropriate assessment of the male fertility status
Crafa, A., CANNARELLA, R., VIGNERA, S. L., Barbagallo, F., CONDORELLI, R. A., & CALOGERO, A. E. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03650-2 · Cited by 13
Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States
Chen, T., Li, S., & Eisenberg, M. L. (2021) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2021.06.007 · Cited by 12
Park, H. C., Kim, H., Lee, H. S., & Lee, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-87220-z · Cited by 12
Gubbi, S., Al-Jundi, M., Auh, S., Jha, A., Zou, J., Shamis, I., Meuter, L., Knue, M., Türkbey, B., Lindenberg, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1275813 · Cited by 12
De-implementing low-value care in endocrinology
Ospina, N. S., Salloum, R. G., Maraka, S., & Brito, J. P. (2021) · Endocrine · doi:10.1007/s12020-021-02732-y · Cited by 14
Self-citationNarinx, N., Nyamaah, J. A., David, K., Sommers, V., Walravens, J., Fiers, T., Lapauw, B., Decallonne, B., Claessens, F., Uytfanghe, K. V., et al. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-1237 · Cited by 10
“Direct measurement of mFT through IA or RIA techniques, e.g. analog-based mFT techniques, proved unreliable and their use was generally discouraged and, for the time being, considered obsolete [1, 2, 46, 47].”
InfluentialDaza, J., Ahmad, A., Shabir, U., Jing, Z., Shiekh, M., KAUFFMAN, E. C., Guru, K. A., & Hussein, A. A. (2023) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2023.06.002 · Cited by 12
D’Amico, E., Zanghì, A., Calogero, A. E., & Patti, F. (2021) · Multiple Sclerosis Journal · doi:10.1177/13524585211009208 · Cited by 11
Swerdloff, R. S., & Wang, C. (2020) · Andrology · doi:10.1111/andr.12901 · Cited by 13
Self-citationBlackwell, K., Blackwell, M., & Blackwell, T. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01935-1 · Cited by 13
“…defines it as a “clinical syndrome that results from the failure of the testis to produce physiological concentrations of testosterone (T) (T deficiency) and/or a normal number of spermatozoa due to pathology at one or more concentrations of the hypothalamic-pituitary-testicular axis” [33, 34].”
BackgroundPharmacotherapy of male hypogonadism
Rastrelli, G., Vignozzi, L., Corona, G., & Maggi, M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102323 · Cited by 14
Zhong, S.-R., Yang, H.-H., Liao, C.-H., Yang, D., Tu, S.-K., Hung, C.-L., & Liao, C. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s282832 · Cited by 14
Assessment of hypogonadism and its determinants among adult men with type 2 diabetes mellitus
Singh, J., Sahoo, A., Swain, J., Mangaraj, S., Kanwar, J. B., & Manglunia, A. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.05.005 · Cited by 14
Effect of supplemental testosterone use on shoulder arthroplasty infection rates
Su, F., Cogan, C. J., Serna, J., Feeley, B. T., Benjamin, C., & Lansdown, D. A. (2023) · Seminars in Arthroplasty JSES · doi:10.1053/j.sart.2023.06.020 · Cited by 16
Adverse events during testosterone replacement therapy in 95 young hypogonadal thalassemic men.
Sanctis, V. D., Soliman, A. T., Daar, S., & Maio, S. D. (2019) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v90i2.8477 · Cited by 12
“2 nmol/L) will usually benefit from testosterone replacement therapy (TRT) (11).”
BackgroundBjørnebekk, A., Scarth, M., Neupane, S. P., Westlye, L. T., Hullstein, I. R., Thorsby, P. M., & Halvorsen, B. L. (2022) · Neuroendocrinology · doi:10.1159/000526418 · Cited by 13
High estradiol level is associated with erectile dysfunction: A systematic review and meta‐analysis
Wu, X., Liu, G., Zhang, Y., Zhang, W., Huang, H., Jiang, H., & Zhang, X. (2022) · Andrologia · doi:10.1111/and.14432 · Cited by 10
“Reduced testosterone levels could result in sexual dysfunction, particularly in ED (Bhasin et al., 2018).”
BackgroundKresch, E., Patel, M., Lima, T. F. N., & Ramasamy, R. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1918101 · Cited by 13
“While the FDA recommends a starting dose with a wide range of 50 to 400 mg every 2–4 weeks, the Endocrine Society Clinical Practice Guidelines suggest an alternative dosing scheme at 75–100 mg weekly or 150–200 mg every 2 weeks [40,42].”
BackgroundLate-Onset Hypogonadism as Primary Testicular Failure
Swee, D. S., & Gan, E. H. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00372 · Cited by 13
The Interdisciplinary Management of Newly Diagnosed Pituitary Tumors
Jaursch-Hancke, C., Deutschbein, T., Knappe, U. J., Saeger, W., Flitsch, J., & Faßnacht, M. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0015 · Cited by 16
Metadata
- Authors
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- University of Southern California (US)
- VA Puget Sound Health Care System (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Manchester (GB)
- Corresponding author
- Bhasin, Shalender
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-03-17
- Volume
- 103
- Issue
- 5
- Pages
- 1715-1744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791298691
- Cited by
- 1,736
- References
- 169
- Citations by year
- 2026: 263 · 2025: 196 · 2024: 198 · 2023: 199 · 2022: 240 · 2021: 221 · 2020: 201 · 2019: 157 · 2018: 56
- FWCI
- 126.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, male hypogonadism, androgen deficiency, sex hormone-binding globulin, secondary sexual characteristics, treatment monitoring, patient decision-making, pharmacokinetics, sleep apnea, thrombophilia, heart failure, lower urinary tract symptoms, fertility preservation
- MeSH terms
- Aged, Aged, 80 and over, Aging, Blood Chemical Analysis, Diagnostic Techniques, Endocrine, Endocrinology, Humans, Hypogonadism, Male, Middle Aged, Societies, Medical, Testosterone, Evidence-Based Medicine, Hormone Replacement Therapy, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.